Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Gross Margin: 2009-2025

Historic Gross Margin for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to 94.67%.

  • Gyre Therapeutics' Gross Margin fell 157.00% to 94.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 95.48%, marking a year-over-year decrease of 75.00%. This contributed to the annual value of 96.33% for FY2024, which is 41.00% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Gross Margin of 94.67% as of Q3 2025, which was down 1.07% from 95.70% recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Gross Margin ranged from a high of 96.95% in Q2 2024 and a low of -0.89% during Q1 2021.
  • Moreover, its 3-year median value for Gross Margin was 95.95% (2025), whereas its average is 95.93%.
  • As far as peak fluctuations go, Gyre Therapeutics' Gross Margin tumbled by 8,227bps in 2021, and later surged by 9,599bps in 2023.
  • Gyre Therapeutics' Gross Margin (Quarterly) stood at -0.57% in 2021, then surged by 4,792bps to 47.35% in 2022, then spiked by 4,805bps to 95.40% in 2023, then surged by 38bps to 95.78% in 2024, then crashed by 157bps to 94.67% in 2025.
  • Its Gross Margin was 94.67% in Q3 2025, compared to 95.70% in Q2 2025 and 95.95% in Q1 2025.